Actively Recruiting
Randomized Placebo-Controlled Trial Evaluating 2LPAPI4 for Clearing Genital High-Risk HPV Infections in Women Aged 25 to 45
Led by Labo'Life · Updated on 2026-08-27
284
Participants Needed
11
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of 2LPAPI4, an immune regulator, in clearing genital high-risk human papillomavirus HR-HPV infections in women aged 25 to 45. This condition is commonly studied in the cervix and vagina, and since 2025, screening in Belgium uses HPV testing as a primary method for cervical cancer prevention. The trial aims to compare 2LPAPI4 with a placebo to assess its impact on clearing HR-HPV infections over a 12-month period. Participants will be randomly assigned to receive either 2LPAPI4 or a placebo. The treatment involves taking one capsule daily on an empty stomach, 15 to 30 minutes before breakfast, following a sequence of numbered capsules for six continuous months. After the treatment phase, there is a six-month follow-up period to monitor the clearance of HR-HPV infections and cytology normalization. The study plans to include 284 women, divided equally between the two groups. During the study, participants will undergo routine screening visits for cervical cancer prevention, including cytology and HPV testing at baseline, six months, and twelve months. Researchers will track the clearance rates of HR-HPV, changes in cytology results, and safety through adverse event monitoring. The total study duration spans up to 72 months, with 60 months for participant inclusion and 12 months for follow-up to evaluate treatment success and safety outcomes.
CONDITIONS
Brief Title
Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.
Research Team
L
Laura FERTE
C
Charlotte BOLLE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here